

Transcripts expressed using a bicistronic vector pIREShyg2 are sensitized to nonsense-mediated mRNA decay

Yayoi Shikama*¹, Huiyuan Hu^{1,2}, Makiko Ohno¹, Isao Matsuoka^{1,3}, Tsutomu Shichishima^{4,5} and Junko Kimura¹

Abstract

Background: pIREShyg2 has been widely used as a bicistronic expression vector. However, it is not known if the vector would affect the expression of cloned genes via nonsense-mediated mRNA decay (NMD), an mRNA surveillance system that degrades mRNA with a premature termination codon (PTC). In mammalian cells, the induction of NMD requires either a long 3'UTR or the presence of an exon-junction complex downstream of a PTC. The efficiency of NMD is greater when a PTC generates longer 3'UTR. pIREShyg2 provides the first cistron gene with a long 3'UTR consisting of a downstream intervening sequence (IVS), an internal ribosomal entry site (IRES) and the second cistron. Therefore, we hypothesized that the first cistron genes in pIREShyg2 are sensitized to NMD, which affects their expression levels. To examine this hypothesis, cDNAs encoding human granulocyte-macrophage colony-stimulating factor receptor β chain (β c) and its splice variant (β c79), in which the retention of a 79-base intron caused a frameshift generating 18 PTCs, were cloned into pIREShyg2 and stably expressed in a murine cell line, Ba/F3.

Results: Compared with wild-type β c, the mRNA levels of β c79 were less than one tenth and decayed faster. Both translation inhibition and Upf1 knockdown led to significantly greater up-regulation of β c79 than wild-type β c. However, the use of a monocistronic pMT21 vector abolished the up-regulatory effects of translation inhibition and Upf1 knockdown on both wild-type β c and β c79, suggesting that the NMD is attributable to a structural determinant in pIREShyg2. The elimination of the intron and the proximal 3' 17 PTCs did not alter the greater effects of translation inhibition on β c79, suggesting that the first PTC, which determines 3'UTR length, was sufficient to enhance NMD efficiency. Thus, transcripts of PTC-harboring genes with longer 3'UTR are more efficiently degraded by the vector-dependent NMD than those of wild-type genes with relatively shorter 3'UTR, resulting in minimized expression of truncated mutants.

Conclusions: We conclude that pIREShyg2, which sensitizes its bicistronic transcripts to NMD, may be useful for studying NMD but should be avoided when maximum expressions of PTC-harboring genes are required.

Background

Expression vectors containing an internal ribosome entry site (IRES) element have been widely used as bicistronic vectors that provide co-expression of two unrelated reading frames from a single transcript unit [1-6]. A reading frame in a multiple cloning site downstream of a promoter is called the first cistron, and the second cistron is downstream of an IRES element. pIREShyg2 is a bicistronic expression vector that possesses an intervening

sequence (IVS) between the first cistron and an IRES element derived from encephalomyocarditis virus, and a hygromycin resistance gene in the second cistron, which serves as a selection marker for stable transfection. It has been shown that the first cistron gene is expressed at levels comparable to those achieved in a monocistronic vector and initiation of translation is cap-dependent [7]. However, the present study is the first to show that the use of pIREShyg2 affects the mRNA stability of their carrying genes in mammalian cells, potentially leading to their insufficient expression.

Nonsense-mediated mRNA decay (NMD) is a post-transcriptional mRNA quality control system that elimi-

* Correspondence: yayois@fmu.ac.jp

¹ Department of Pharmacology, Fukushima Medical University, Fukushima, Japan

Full list of author information is available at the end of the article

nates aberrant mRNAs harboring premature termination codons (PTCs) within protein coding regions in eukaryotes [8-10] to protect the cells from accumulation of harmful or nonfunctional C-terminally truncated polypeptides [11,12]. The degradation occurs in a translation-dependent manner when translation is initiated in an mRNA cap-dependent manner [13,14]. In mammalian cells, two determinants have been identified that distinguish "premature" termination codons from "normal" termination codons and provide a protective advantage to the normal termination codon [15]. One is the presence of an exon-junction complex (EJC) more than 50 nucleotides downstream of a termination codon [16-23]. Induction of NMD requires the association between the EJC and the protein complex bound to the ribosome stalled at a PTC, which contains essential proteins to trigger NMD such as Upf1, eukaryotic release factors, and SMG1 [13,24-28]. Because normal termination codons generally reside either in the final exon or within 50 nucleotides upstream of the 3'-end in the penultimate exon, the transcripts coding wild-type proteins are able to escape NMD [16,29]. Another determinant is the distance between the stop codon and a poly(A) region [30-33]. Normal termination requires the interaction between the terminating ribosomal complex and the poly(A)-binding proteins (PABP), which leads to faster release of a terminating ribosome from mRNA [34]. A ribosomal complex at a PTC fails to interact with PABPs because of the relatively longer distance from the poly(A) region, resulting in prolonged association with mRNA, which stimulates NMD [28]. Recently, it has been reported that the length between a termination codon and poly(A) region affects NMD efficiency, showing that longer 3'UTR induces greater NMD activity [30-32].

Recently, we identified a novel splice variant of the granulocyte-macrophage colony-stimulating factor receptor (GMR) β chain (β c) in patients with myelodysplastic syndrome, a clonal hematopoietic disorder [35].

The splice variant (β c79) retained the 79-base intron V, resulting in a frameshift that introduced eighteen PTCs downstream of the retained intron. When the cDNAs encoding the β c79 or wild-type β c were cloned into the first cistron of pIRESHyg2 vector and stably expressed in a murine hematopoietic cell line, Ba/F3, β c79 mRNA levels were significantly reduced compared with those observed for wild-type β c. We show here that the pIRESHyg2 vector sensitizes the first cistron genes to NMD and, interestingly, that β c79 with PTCs was far more sensitive to the vector-dependent NMD resulting in minimized expression levels of the PTC-harboring gene.

Results

Intron V is not spliced out in β c79 clones

To determine whether the intron V was spliced in the cells stably expressing β c79, we analyzed the presence of intron V in the integrated DNA and respective RNA isolated from each clone by PCR. The locations of the sequences corresponding to the primers are shown in Figure 1 and Table 1. PCR with 2S/2A primers that flank intron V distinguished β c79 cDNA from wild-type β c cDNA by the larger fragment size (446 bp versus 387 bp) (Figure 2a). In RNA from all β c79 clones, only the larger size of PCR products was detectable. The absence of a 387-bp band suggested that intron V in β c79 mRNA was not spliced out in Ba/F3 transfectants resulting in the generation of 18 PTCs. The unspliced intron V in β c79 mRNA was also detected by PCR using a 3S primer that was complementary to the 5'-end of intron V. All RNA samples without reverse transcription failed to generate any PCR products (data not shown).


β c79 mRNA decays faster than wild-type β c mRNA

We determined the amounts of integrated DNA and respective transcripts for wild-type β c or β c79 by real-time PCR with 1S/1A primers. Compared with a clone expressing wild-type β c 5C, β c79 clones mE and m821

Table 1: Sequences of primers.

Primer	Sequence (5'T 3')	Nucleotide position
1S	TACCTGTGCTGCCTGCTG	1910-1928 in β c
1A	GAGACATAACCAGAGGCCACT	2136-2166 in β c
2S	TGCCAGAGTTTTGTCGTCAC	326-345 in β c
2A	CTTGCTGGGACGTCCTGAGA	692-712 in β c
3S	CTTGGGAGGTAGGAACCACG	570-(i)12* in β c
HygRS	TGGATATGTCCTGCGGGTAA	2073-2092 in IRESHyg2
HygRA	TTCCTTGCGGTCCGAATG	2345-2362 in IRESHyg2
EpoRS	CCACTGCTTACTGGCTTATCG	838-859 in IRESHyg2
EpoRA	TGCTCTCAAACCTGGGGTCCG	119-139 in EpoR


*(i), the nucleotide position in the intron V-derived sequence



had similar amounts of integrated β c79 cDNA, and about half of that amount was found in clones m951 and 63m (data not shown). However, as shown in Figure 2b, in all four β c79 clones, RNA levels for β c79 were less than 10% of that measured for wild-type β c mRNA in 5C. Two other independent clones of wild-type β c, C10E and FC10, showed higher mRNA levels than 5C. We next added 5,6-dichlorobenzimidazolone-1- β -D-ribofuranoside (DRB), a transcription inhibitor, to mE and 5C cells and determined the steady-state amounts of wild-type β c and β c79 transcripts over time. Wild-type transcripts (relative to GAPDH) decreased to 50% of the initial level after two hours, while β c79 transcripts (relative to GAPDH) in mE fell to half the initial level after one hour (Figure 2c). The reduction of β c79 transcripts was significantly greater than that of wild-type β c at the two and three hour time points. Given that intron V was not spliced out in Ba/F3 transfectants, we hypothesized that the presence of 18 PTCs in β c79 mRNA upstream of the pIRESHyg2-derived IVS resulted in NMD induction.

Upregulation of β c79 transcripts by a translation inhibitor is greater than that of wild-type β c

It was shown that the treatment of cells with translation inhibitors result in abrogation of NMD that occurs in a translation-dependent manner [36,37]. Therefore, to examine whether NMD is implicated in the degradation of β c79 mRNA, mE cells were incubated with various concentrations of puromycin, a translation inhibitor. The



amounts of β c79 transcripts relative to those of GAPDH increased in a dose-dependent manner, and the maximum level (30.3 ± 1.4 -fold) was observed with 20 μ g/mL puromycin (Figure 3). Emetin and cycloheximide (CHX), two other inhibitors, also induced a dose-dependent increase in β c79 transcripts and maximum effects similar to those induced by puromycin (31.0 ± 7.0 -fold, and 35.0 ± 1.4 -fold, respectively) (Figure 3).

To compare the effects of the translation inhibitor between β c79 and wild-type β c, mE and 63m clones expressing β c79 and clone 5C expressing wild-type β c were incubated with 100 μ g/mL puromycin, and β c-specific transcripts were quantified at various time points (Figure 4a). A time-dependent increase in β c-specific transcripts was observed in all three clones. At 4.5 hour time point, the increase of β c79 transcripts in both mE (41.4 ± 6.2 -fold, $p < 0.05$) and 63m (39.6 ± 5.4 -fold, $p < 0.05$) became significantly greater than that of wild-type transcripts in 5C (11.4 ± 1.3 -fold). The different up-regulatory response between β c79 and wild-type β c was confirmed in two other clones of β c79 and wild-type β c




Figure 3 Dose-response relationship between $\beta c79$ transcripts and translation inhibitors. The $\beta c79$ -expressing clone mE was incubated with various concentrations of puromycin, emetin, and CHX for 4.5 hours. The ratios of βc -specific transcripts to GAPDH transcripts were measured by real-time RT-PCR with 1S/1A primers. The ratios in NMD inhibitor-treated cells were divided by those in untreated cells, which are presented as fold increases. The mean values \pm S.E.M. (error bars) were obtained from 3 to 4 independent experiments.

(Table 2). Among four $\beta c79$ -expressing clones, there was no significant difference in the increase of $\beta c79$ transcripts induced by puromycin. After treatment for 8 hours, the $\beta c79$ mRNA levels in mE and 63m further increased to 184.3 ± 27.9 -fold and 115.7 ± 8.0 -fold, respectively. In contrast, there was only an 11.9 ± 2.9 -fold increase in wild-type βc transcripts in 5C. The resulting mRNA levels of $\beta c79$ in mE and 63m became 66% and 26% of wild-type βc , respectively (Figure 4b).

To confirm that the effects of NMD inhibition were greater on $\beta c79$ than on wild-type βc , siRNA targeting




Figure 4 Time course of βc transcript levels in response to puromycin. (a) Two $\beta c79$ clones, mE and 63m, and a wild-type βc clone 5C were incubated with 100 $\mu g/mL$ puromycin for the indicated periods, and the ratios of βc -specific transcripts to endogenous GAPDH transcripts were measured by real-time RT-PCR with 1S/1A primers. The values at 0 hours are plotted as 1.0. The average values \pm S.E.M. (error bars) were obtained from 3 to 8 experiments. * and **: significantly higher than the value in 5C incubated for the same time with $p < 0.05$ and $p < 0.01$, respectively. (b) After 8-hour treatment, the βc -specific transcripts were quantified and normalized by those of GAPDH. The values from mE and 63m cells were compared with those from 5C cells, which are plotted as 1.0. (c) The siRNA targeting Upf1 was introduced into 5C and mE cells, and the amounts of Upf1 and βc transcripts were quantified after 48 hours. The presented data are the average values and S. E. M. (error bars) from four different experiments. *: significantly different ($p < 0.05$).

Upf1, an essential component of the NMD machinery, was used in mE and 5C cells. In both Upf1 siRNA-treated mE and 5C cells, the Upf1 RNA levels became 25-30% those of the control siRNA-treated cells after 24 hours, and 50-55% after 48 hours. As shown in Figure 4c, the reduction in Upf1 for 48 hours resulted in a 3.5 ± 0.4 -fold up-regulation of $\beta c79$ transcripts in mE, which was sig-

Table 2: Effects of incubation with 100 $\mu g/ml$ puromycin for 4.5 hours.

Wild-type βc clones	Increase (-fold)	$\beta c79$ clones	Increase (-fold)
5C	11.4 ± 1.3	mE	41.4 ± 6.2
C10E	9.6 ± 1.5	63 m	39.6 ± 5.4
FC10	7.3 ± 0.7	m821	33.3 ± 1.2
		m951	49.6 ± 3.2

Presented as average values and S.E.M. from three to eight independent experiments

nificantly greater than that of wild-type β c in 5C (1.9 ± 0.2 -fold, $p < 0.05$).

Vector sensitizes both wild-type β c and β c79 to NMD

Although wild-type β c transcripts were less affected by NMD inhibition than β c79 transcripts, treatment with puromycin always resulted in a 7 to 12-fold increase in the amount of wild-type β c transcripts in Ba/F3 cells. Interestingly, pIRESHyg2 provides an IVS, an IRES and a hygromycin resistance gene downstream of the normal termination codon in wild-type β c. We wondered whether the structural characteristics of pIRESHyg2 might cause NMD in wild-type β c. To test this hypothesis, cDNA of the wild-type β c was cloned into a monocistronic pMT21 vector that did not have them between its cloning site and poly(A) region (Figure 5a), and stably expressed in Ba/F3 cells. In contrast to what we observed when β c was cloned into pIRESHyg2 (11.4 ± 1.3 -fold


increase), transcripts of wild-type β c cloned into pMT21 showed only a slight increase (1.4 ± 0.2 -fold) after incubation with puromycin for 4.5 hours. This difference was highly significant ($p < 0.01$) (Figure 5b). The siRNA-mediated Upf1 knockdown also resulted in a 0.81 ± 0.02 -fold change in the wild-type β c in pMT21, which was significantly lower than that in pIRESHyg2 (1.8 ± 0.2 -fold, $p < 0.05$) (Figure 5c). When β c79 was cloned into pMT21 instead of pIRESHyg2, the up-regulatory response of β c79 diminished to 1.9 ± 0.2 -fold, which was not significantly different from that of wild-type β c cloned into pMT21 (Figure 5b).


We next examined whether pIRESHyg2-dependent NMD affected the expression of the second cistron. The transcripts of hygromycin resistance gene (HygR) in the cells expressing wild-type β c was increased 8.7 ± 1.6 -fold ($n = 4$) by puromycin treatment for 4.5 hours. The increase of HygR transcripts in β c79 clones was 39.7 ± 1.3 -fold ($n = 3$), which was significantly greater than that in wild-type cells ($P < 0.05$).

Replacement of intron V with a single nucleotide or elimination of the intron preserving a 5' single PTC fail to alter NMD effects on β c79

To examine whether the greater NMD activity on β c79 was attributable to intron V retained in β c79, the 79 nucleotides of intron V were replaced by a single guanylate residue as indicated by "G" in Figure 6a. Although the 78 nucleotides of the intronic sequence had been deleted in the resulting cDNA (β c-G), β c-G still retained the same 18 PTCs as β c79 (Figure 6a). β c-G was cloned into pIRESHyg2 and stably expressed in Ba/F3 cells. As shown in Figure 6b, puromycin treatment for 4.5 hours increased β c-G transcripts 38.6 ± 2.0 -fold, which was significantly higher than the increase in 5C ($p < 0.05$) but not different from that in mE (41.4 ± 5.4 -fold). This result suggests that the presence of intron V per se is not directly involved in mediating greater NMD on β c79 than on wild-type β c. We next wanted to test whether preservation of the first PTC mutation (position 259) in a variant of β c79 in which intron V had been completely deleted still conferred NMD to the expressed transcripts (Figure 6a). The resulting cDNA, β c258, was stably expressed using pIRESHyg2. The up-regulatory effect of puromycin on β c258 (41.6 ± 10.9 -fold) was not significantly different from that on β c79 (Figure 6b).

Lastly, we examined whether the pIRESHyg2-dependent NMD was specific to β c. cDNAs of the wild type and a truncated form (EpoR215) of mouse erythropoietin receptor (EpoR), which are shown in Figure 6c, were subcloned into pIRESHyg2 and stably expressed in Ba/F3. The puromycin treatment for 4.5 hours increased wild-type EpoR transcripts 12.8 ± 1.9 -fold. In contrast, EpoR215 was increased 84.8 ± 16.5 -fold, which was sig-





nificantly greater than that of wild type ($p < 0.05$). (Figure 6d).

Discussion

This study reveals that an expression vector can destabilize the mRNA of its carrying gene via NMD resulting in minimized expression levels.

When β c79 and wild-type β c were stably expressed using a commercial expression vector, pIRESHyg2, the mRNA levels of β c79 were less than one tenth those of wild-type β c. mRNA expression levels are regulated

through transcriptional and posttranscriptional control mechanisms [36-38], and mRNA stability is determined by posttranscriptional regulation, which varies from one mRNA species to another [39,40]. The diversity in the transcriptional activities can be due to their integration sites [41,42]. However, the low β c79 expression was uniformly seen in all clones tested, and the transcripts of β c79 decayed faster than those of wild-type β c. These indicate that the posttranscriptional mechanism was involved in the low expression levels of β c79 mRNA. The RT-PCR indicated that 79-base intron V was retained in the β c79 transcripts, generating 18 PTCs and longer 3' UTR in β c79 than in wild-type. Since transcripts with longer 3'UTR are more sensitive to NMD in mammalian cells [30-33], we examined whether destabilization of β c79 mRNA via NMD caused the suppression of β c79 expression levels.

The faster decay of β c79 mRNA is attributable to greater effects of NMD on β c79 than on wild-type β c. Since NMD is a translation-dependent process, translation inhibitors have been used to abrogate NMD, and the increase in mRNA levels in the presence of a translation inhibitor is considered to reflect the effects of NMD [43,44]. The up-regulation of β c79 transcripts by three different translation inhibitors indicated that β c79 mRNA was degraded by NMD. Furthermore, the up-regulatory effects of the translation inhibition were significantly greater on β c79 than on wild-type β c, which diminished the difference in mRNA levels between β c79 and wild-type β c. The greater effects of NMD on β c79 were also confirmed by siRNA-mediated NMD inhibition. Transcripts of β c79 were thus degraded more efficiently by NMD than those of wild-type β c, which resulted in lower mRNA levels of β c79.

Wild-type β c was also sensitive to NMD when expressed by pIRESHyg2, because both translation inhibition and Upf1 knockdown increased transcripts of wild-type β c cloned into pIRESHyg2. These up-regulatory effects were abrogated when pMT21 was used instead of pIRESHyg2. This observation indicates that the vector sensitized wild-type β c to NMD. Because β c79 also became insensitive to NMD in pMT21, we concluded that the IRES vector rendered its first cistronic genes sensitive to NMD.

There may be additional determinants for the stronger NMD to β c79 in the pIRESHyg2 system. Although the nucleotide in the position immediately downstream of the termination codon was shown to enhance the up-regulatory effects of translation inhibition in the order $G < U, A < C$ [45,46], it does not seem relevant to the difference between β c79 and the wild-type β c, because the nucleotide following the first PTC in β c79 and the one after the normal stop codon in wild-type β c are both G. The replacement of the intron V with a single nucleotide

did not alter the up-regulatory effects of NMD inhibition, suggesting that the intron V was not responsible for greater NMD effects on β c79. The β c258, which had a single PTC at a position similar to the distal 5' PTC in β c79 but no frameshift, elicited a degree of NMD similar to that of β c79, indicating that the 5' single PTC is sufficient to induce greater NMD effects on β c79. This is comparable to recent reports in which more efficient NMD was induced when a PTC was generated closer to 5'-end resulting in longer 3'UTR length [30-32].

Lastly, it is unlikely that pIRESHyg2-related NMD induction is specific to β c cDNA. When wild-type EpoR was stably expressed in the same cell line using pIRESHyg2, upregulation of its transcripts was induced by puromycin, suggesting that wild-type EpoR in pIRESHyg2 vector was also a target of NMD. The effects of puromycin were enhanced on EpoR215 that possessed longer 3'UTR.

Thus, the expression levels of genes encoding truncated mutants, in which PTCs generate longer 3'UTRs, can be significantly reduced via vector-dependent NMD compared with wild-type genes that generally have shorter 3'UTR.

Conclusions

We show here for the first time the NMD effects associated with an expression vector in a mouse hematopoietic cell line. Although the IRES vector may be an interesting system for studying NMD, our study warns us that the choice of the IRES vector leads to undesirable consequences especially when maximum expression of a truncated mutant with a long 3'UTR is required in mammalian cells.

Methods

Plasmid constructions

The cDNA of full-length GM-CSF receptor β c subunit (kindly provided by Dr. Sumiko Watanabe, University of Tokyo, Tokyo, Japan) was subcloned into the SmaI site of pIRESHyg2, an expression vector (Clontech Laboratories, Inc., Palo Alto, USA), as shown in Figure 1. The β c79 cDNA containing intron V at nucleotide position 578 was isolated from a patient with myelodysplastic syndromes and subcloned into a plasmid vector, pCR4-TOPO (Invitrogen Corp, Carlsbad, USA) to confirm its sequence. The Acc I site to BssH II fragment of β c79, which contains intron V, was used to replace the Acc I-BssH II fragment of wild-type β c in pIRESHyg2, thus generating the β c79-IRESHyg2 construct.

Wild-type β c in pMT21 was obtained using the construct of the EpoR- β c hybrid receptor in pMT21, which was prepared in a previous study [47]. The hybrid receptor consisted of 756 bases proximal to 5' of EpoR cDNA and 1655 bases proximal to 3' of β c cDNA. The fragment

between EcoRI and BssHII sites of the hybrid receptor in pMT21, which contained the EpoR-coding region, was substituted to cDNA of wild-type β c or β c79 in pcDNA3.1 that possessed an EcoRI site in the multiple cloning region. The obtained full-length β c cDNA in pMT21 was sequenced prior to transfection.

cDNA of murine EpoR, a generous gift from Dr. Alan D'Andrea (Dana-Farber Cancer Institute, Boston, USA), was inserted between Eco47III and EcoRV sites in pIRESHyg2 vector.

The constructs harboring a single PTC were generated using QuickChange II XL Site-Directed Mutagenesis Kit (Stratagen-An Agilent Technologies Company, La Jolla, USA), and sequenced prior to transfection.

Transfection

The constructs were introduced into Ba/F3 cells, an IL-3-dependent mouse hematopoietic progenitor cell line, as described previously [35]. The hygromycin-resistant cells were subjected to repeated limiting dilutions to establish independent clones.

Inhibitions of transcription and translation

Cells (grown at 1×10^6 cells/ml) were cultured in the presence of 25 μ g/mL DRB (Sigma-Aldrich Corp., St. Louis, MO), a transcription inhibitor, or the indicated concentrations of translation inhibitors: emetin (Sigma), puromycin (Sigma), or CHX (Sigma).

Upf1 knockdown by siRNA induction

The siRNA corresponding to mouse Upf1 mRNA was designed as follows: sense GAUGCAGUCCGUUCCACUtt and antisense GAUGGAACGGAACUGCAUCtt (nucleotide [2084-2102](#); Genbank Accession No. [AY597038](#)). One and a half μ g control siRNA (Ambion Inc., Austin, USA) or siRNA targeting to Upf1 was introduced into 0.2×10^5 cells suspended in 75 μ L siPORT™ siRNA Electroporation Buffer (Ambion) by square-pulse electroporation (250 mV 30 msec) using a Gene Pulser (Bio-Rad Laboratories, Inc., Hercules, USA). After 24 and 48 hours, the transcripts of β c and Upf1 were quantified.

Isolation of DNA and RNA

Genomic DNA was isolated from each clone using the Generation DNA purification system kit (Gentra Systems, Inc., Minneapolis, MN). Total cellular RNA was isolated by acid guanidium thiocyanate-phenol-chloroform extraction methods [48]. All RNA samples were treated with RNase-free DNaseI (Takara Bio, Inc., Otsu, Japan) prior to further analyses.

PCR, and real-time PCR

The total cellular RNA was incubated in reverse-transcription buffer including random primer, dNTP, and RNAase inhibitor, with or without reverse transcriptase

at 37°C for 1 hour as previously described [49], and subjected to PCR analyses. The annealing temperatures for detection of β c and others were 62°C and 56°C, respectively. The samples prepared without the enzyme were used to examine DNA contamination in the RNA samples. The sequences of PCR primers are presented in Table 1.

The β c-specific transcripts were quantified by real-time PCR in duplicate using SYBR Premix Ex Taq (Takara Bio. Inc.), 1S/1A primers (Table 1), and LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also quantified as an internal control. The real-time PCR protocol included an initial denaturing step at 95°C for 30 seconds, 40 cycles of 5-second denaturing, 10-second annealing and 15-second extension, a cooling step to 65°C for 15 seconds followed by a heating step for dissociation analysis. The annealing temperatures for quantification of β c and others were 62°C and 56°C, respectively. Crossing points were determined by the second derivative maximum method. The amounts of targets were calculated based on standard curves which were generated by the amplification of sequentially diluted cDNA with each PCR primer pair. In every experiment, it was confirmed that the first derivatives of the dissociation curves had only a single peak.

Statistical analysis

The comparison of data among more than three clones was done by Scheffe's test. The Mann-Whitney test was used for the comparison between two groups.

Authors' contributions

YS conceived and designed the study. YS and HH quantified transcripts. YS, HH, and MO constructed a mutant cDNAs. IM and JK supervised the study design and data analyses. TS participated in the identification of the variant and the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Dr. Ikuo Wada (Fukushima Medical University, Fukushima, Japan) for constructive comments and technical support for transfection experiments, Dr. Bernard Mathey-Prevot (Duke University School of Medicine, Durham, USA) and Dr. Yuichi Endo (Fukushima Medical University) for helpful advice in the preparation of the manuscript, Dr. Midori Yatabe (Fukushima Medical University) for the correction of English, Dr. Tomoyuki Ono and Ms. Sanae Sato (Fukushima Medical University) for technical assistance. This work was supported by the Fukushima Medical Research Fund (Japan), NISHINOMIYA Basic Research Fund (Japan), and a grant from the Smoking Research Foundation (Japan).

Author Details

¹Department of Pharmacology, Fukushima Medical University, Fukushima, Japan, ²Department of Pharmaceutical Toxicology, School of Pharmaceutical Sciences, China Medical University, Shenyang, China, ³The Laboratory of Pharmacology, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan, ⁴Department of Cardiology and Hematology, Fukushima Medical University, Fukushima, Japan and ⁵Fukushima Research Institute of Environment and Medicine, Futaba, Japan

Received: 1 June 2009 Accepted: 1 June 2010

Published: 1 June 2010

References

1. Davies MV, Kaufman RJ: Internal translation initiation in the design of improved expression vectors. *Curr Opin Biotechnol* 1992, **3**:512-517.
2. Dirks W, Wirth M, Hauser H: Dicistronic transcription units for gene expression in mammalian cells. *Gene* 1993, **128**:247-249.
3. Mountford PS, Smith AG: Internal ribosome entry sites and dicistronic RNAs in mammalian transgenesis. *Trends Genet* 1995, **11**:179-184.
4. Borman AM, Bailly JL, Girard M, Kean KM: Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation *in vitro*. *Nucleic Acids Res* 1995, **23**:3656-3663.
5. Martinez-Salas E: Internal ribosome entry site biology and its use in expression vectors. *Curr Opin Biotechnol* 1999, **10**:458-464.
6. Fussenegger M, Bailey J, Hauser H, Mueller PP: Genetic optimization of recombinant glycoprotein production by mammalian cells. *Trends Biotechnol* 1999, **17**:35-42.
7. Hennecke M, Kwissa M, Metzger K, Oumard A, Kröger A, Schirmbeck R, Reimann J, Hauser H: Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. *Nucleic Acids Res* 2001, **29**:3327-3334.
8. Behm-Ansmant I, Kashima I, Rehwinkel J, Sauliere J, Wittkopp N, Izaurralde E: mRNA quality control: an ancient machinery recognizes and degrades mRNAs with nonsense codons. *FEBS Lett* 2007, **581**:2845-2853.
9. Chang YF, Imam JS, Wilkinson MF: The nonsense-mediated decay RNA surveillance pathway. *Annu Rev Biochem* 2007, **76**:51-74.
10. Isken O, Maquat LE: Quality control of eukaryotic mRNA: safeguarding cells from abnormal mRNA function. *Genes Dev* 2007, **21**:1833-1856.
11. Wilkinson MF: A new function for nonsense-mediated mRNA-decay factors. *Trends Genet* 2005, **21**:143-148.
12. Pan Q, Saltzman AL, Kim YK, Misquitta C, Shai O, Maquat LE, Frey BJ, Blencowe BJ: Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. *Genes Dev* 2006, **20**:153-158.
13. Ishigaki Y, Li X, Serin G, Maquat LE: Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense-mediated decay in mammalian cells are bound by CBP80 and CBP20. *Cell* 2001, **106**:607-617.
14. Sato H, Hosoda N, Maquat LE: Efficiency of the pioneer round of translation affects the cellular site of nonsense-mediated mRNA decay. *Mol Cell* 2008, **29**:255-262.
15. Shyu AB, Wilkinson MF, van Hoof A: Messenger RNA regulation: to translate or to degrade. *EMBO J* 2008, **27**:471-481.
16. Nagy E, Maquat LE: A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. *Trends Biochem Sci* 1998, **23**:198-199.
17. Carter MS, Li S, Wilkinson MF: A splicing-dependent regulatory mechanism that detects translation signals. *EMBO J* 1996, **15**:5969-5975.
18. Zhang J, Sun X, Qian Y, LaDuca JP, Maquat LE: At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: a possible link between nuclear splicing and cytoplasmic translation. *Mol Cell Biol* 1998, **18**:5272-5283.
19. Neu-Yilik G, Gehring NH, Thermann R, Frede U, Hentze MW, Kulozik AE: Splicing and 3' end formation in the definition of nonsense-mediated decay-competent human beta-globin mRNPs. *EMBO J* 2001, **20**:532-540.
20. Thermann R, Neu-Yilik G, Deters A, Frede U, Wehr K, Hagemeier C, Hentze MW, Kulozik AE: Binary specification of nonsense codons by splicing and cytoplasmic translation. *EMBO J* 1998, **16**:3484-3494.
21. Lykke-Andersen J, Shu MD, Steitz JA: Communication of the position of exon-exon junctions to the mRNA surveillance machinery by the protein RNPS1. *Science* 2001, **293**:1836-1839.
22. Maquat LE, Li X: Mammalian heat shock p70 and histone H14 transcripts, which derive from naturally intronless genes, are immune to nonsense-mediated decay. *RNA* 2001, **7**:445-456.
23. Brocke KS, Neu-Yilik G, Gehring NH, Hentze MW, Kulozik AE: The human intronless melanocortin 4-receptor gene is NMD insensitive. *Hum Mol Genet* 2002, **11**:331-335.
24. Ohnishi T, Yamashita A, Kashima I, Schell T, Anders KR, Grimson A, Hachiya T, Hentze MW, Anderson P, Ohno S: Phosphorylation of hUPF1 induces

- formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. *Mol Cell* 2003, **12**:1187-1200.
25. Gehring NH, Neu-Yilik G, Schell T, Hentze MW, Kulozik AE: **Y14 and hUpf3b form an NMD-activating complex.** *Mol Cell* 2003, **11**:939-949.
 26. Palacios IM, Gatfield D, St Johnston D, Izaurralde E: **An eIF4AIII-containing complex required for mRNA localization and nonsense-mediated mRNA decay.** *Nature* 2004, **427**:753-757.
 27. Kashima I, Yamashita A, Izumi N, Kataoka N, Morishita R, Hoshino S, Ohno M, Dreyfuss G, Ohno S: **Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay.** *Genes Dev* 2006, **20**:355-367.
 28. Behm-Ansmant I, Izaurralde E: **Quality control of gene expression: a stepwise assembly pathway for the surveillance complex that triggers nonsense-mediated mRNA decay.** *Genes Dev* 2006, **20**:391-398.
 29. Keeling KM, Lanier J, Du M, Salas-Marco J, Gao L, Kaenjak-Angeletti A, Bedwell DM: **Leaky termination at premature stop codons antagonizes nonsense-mediated mRNA decay in *S. cerevisiae*.** *RNA* 2004, **10**:691-703.
 30. Bühler M, Steiner S, Mohn F, Paillusson A, Mühlemann O: **EJC-independent degradation of nonsense immunoglobulin- μ mRNA depends on 3' UTR length.** *Nat Struct Mol Biol* 2006, **13**:462-464.
 31. Behm-Ansmant I, Gatfield D, Rehwinkel J, Hilgers V, Izaurradle E: **A conserved role for cytoplasmic poly(A)-binding protein 1 (PABC1) in nonsense-mediated mRNA decay.** *EMBO J* 2007, **26**:1591-1601.
 32. Longman D, Plasterk RH, Johnstone IL, Cáceres JF: **Mechanistic insights and identification of two novel factors in the *C. elegans* NMD pathway.** *Genes Dev* 2007, **21**:1075-1085.
 33. Eberle AB, Stalder L, Mathys H, Orozco RZ, Mühlemann O: **Posttranscriptional gene regulation by spatial rearrangement of the 3' untranslated region.** *PLoS Biol* 2008, **6**:849-859.
 34. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A: **A faux 3'-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay.** *Nature* 2004, **432**:112-118.
 35. Shikama Y, Shichishima T, Matsuoka I, Jubinsky PT, Sieff CA, Maruyama Y: **Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common β chain in neutrophils of myelodysplastic syndromes.** *J Leukocyte Biol* 2005, **77**:811-819.
 36. Wang Y, Liu CL, Storey JD, Tibshirani RJ, Herschlag D, Brown PO: **Precision and functional specificity in mRNA decay.** *Proc Natl Acad Sci USA* 2002, **99**:5860-5865.
 37. Raghavan A, Ogilvie RL, Reilly C, Abelson ML, Raghavan S, Vasdevani J, Krathwohl M, Bohjanen PR: **Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes.** *Nucleic Acids Res* 2002, **30**:5529-5538.
 38. Gutierrez RA, Ewing RM, Cherry JM, Green PJ: **Identification of unstable transcripts in Arabidopsis by cDNA microarray analysis: rapid decay is associated with a group of touch- and specific clock-controlled genes.** *Proc Natl Acad Sci USA* 2002, **99**:11513-11518.
 39. Mitchell P, Tollervey D: **mRNA stability in eukaryotes.** *Curr Opin Genet Dev* 2000, **10**:193-198.
 40. Wilusz CJ, Wormington M, Peltz SW: **The cap-to-tail guide to mRNA turnover.** *Nat Rev Mol Cell Biol* 2001, **2**:237-246.
 41. Feng YQ, Lorincz MC, Fiering S, Grealley JM, Bouhassira EE: **Position effects are influenced by the orientation of a transgene with respect to flanking chromatin.** *Mol Cell Biol* 2001, **21**:298-309.
 42. Eszterhas SK, Bouhassira EE, Martin DI, Fiering S: **Transcriptional interference by independently regulated genes occurs in any relative arrangement of the genes and is influenced by chromosomal integration position.** *Mol Cell Biol* 2002, **22**:469-479.
 43. Noensie EN, Dietz HC: **A strategy for disease gene identification through nonsense-mediated mRNA decay inhibition.** *Nat Biotech* 2001, **19**:434-439.
 44. Carter MS, Doskow J, Morris P, Li S, Nihm RP, Sandstedt S, Wilkinson MF: **A regulatory mechanism that detects premature nonsense codons in T-cells receptor transcripts in vivo is reversed by protein synthesis inhibitors in vitro.** *J Biol Chem* 1995, **270**:28995-29003.
 45. Bonetti B, Fu L, Moon J, Bedwell DM: **The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in *Saccharomyces cerevisiae*.** *J Mol Biol* 1995, **251**:334-345.
 46. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Arkins JF: **Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy.** *Ann Neurol* 2000, **48**:164-169.
 47. Shikama Y, Barber DL, D'Andrea AD, Sieff CA: **A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines.** *Blood* 1996, **88**:455-464.
 48. Chomczynski P, Sacchi N: **Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.** *Anal Biochem* 1987, **162**:156-159.
 49. Hu H, Shikama Y, Matsuoka I, Kimura J: **Terminally differentiated neutrophils predominantly express Survivin-2a, a dominant-negative isoform of Survivin.** *J Leukocyte Biol* 2008, **83**:393-400.

doi: 10.1186/1471-2199-11-42

Cite this article as: Shikama et al., Transcripts expressed using a bicistronic vector pIRESHyg2 are sensitized to nonsense-mediated mRNA decay *BMC Molecular Biology* 2010, **11**:42

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

